The latest biotech news

News and Trends 23 Jun 2023

New disease characteristic seen as NMD Pharma reports Charcot-Marie-Tooth results

NMD Pharma A/S, a clinical stage biotech company developing first-in-class, small molecule ClC-1 inhibitors for neuromuscular disorders, has presented results from ESTABLISH1, an observational study of neuromuscular function in patients with the inherited neurological conditions Charcot-Marie-Tooth (CMT) types 1 and 2. The results were revealed in a poster presentation at the Peripheral Nerve Society Annual […]

June 23, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 23 Jun 2023

Breakthrough treatment for skin infections?

A research team led by Kelvin Yeung from the Department of Orthopaedics and Traumatology, School of Clinical Medicine, LKS Faculty of Medicine, the University of Hong Kong (HKUMed) has designed a new microneedle patch that provides an effective non-antibiotic approach for the treatment of skin infections. The design engineered with ultrasound-responsive zinc-based metal-organic framework (MOF) […]

June 23, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 23 Jun 2023

European Coalition for Access to Comprehensive Genomic Profiling launched

The European Confederation of Pharmaceutical Entrepreneurs (EUCOPE) along with Exact Sciences, Guardant Health, Illumina, MSD and Novartis, have launched the European Coalition for Access to Comprehensive Genomic Profiling (ECGP), to improve cancer care through increased routine clinical access and reimbursement of Comprehensive Genomic Profiling (CGP) in Europe. CGP is a method of testing tumors that […]

June 23, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 23 Jun 2023

Sarepta gets approval for first gene therapy for Duchenne muscular dystrophy

Sarepta Therapeutics, Inc. has announced U.S. Food and Drug Administration (FDA) accelerated approval of ELEVIDYS (delandistrogene moxeparvovec-rokl), an Adeno-associated virus (AAV)-based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with Duchenne muscular dystrophy (DMD) with a confirmed mutation in the DMD gene. This indication is approved under accelerated approval […]

June 23, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 23 Jun 2023

SandboxAQ launches new division to boost drug development

After several years of stealth development, SandboxAQ has announced its bio-pharma molecular simulation division, AQBioSim, and some of its customers. The division is helping bio-pharma and research institutions achieve breakthroughs in treatments for cancer, Alzheimer’s, Parkinson’s, and other conditions. The company is currently working with biopharma companies and university research labs, including AstraZeneca, Sanofi and […]

June 23, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 22 Jun 2023

Alchemab Therapeutics unveils Alzheimer’s candidate

Alchemab Therapeutics, an antibody discovery company identifying naturally occurring antibodies from individuals resilient to disease, has unveiled data on ATLX-1088, its newly-discovered preclinical Alzheimer’s candidate, at the Antibody Industrial Symposium in Tours, France. ATLX-1088 is a potential first-in-class human antibody targeting CD33, a cell surface protein thought to have a key role in Alzheimer’s disease. […]

June 22, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 22 Jun 2023

Ovarian cancer study finds key genes for potential treatments

New study is increasing knowledge of why some women with the most lethal form of ovarian cancer respond much better to treatment than others. Researchers at Imperial College London in the U.K. have confirmed that the tumors of some women with high-grade serious ovarian cancer (HGSOC) contain a type of lymphoid tissue – known as […]

June 22, 2023 - 4 minutesmins - By Jim Cornall

News and Trends 22 Jun 2023

FDA approves type 2 diabetes drug for children 10 and older

The U.S. Food and Drug Administration (FDA) has approved Jardiance (empagliflozin) 10 mg and 25 mg tablets to lower blood sugar along with diet and exercise in children 10 years and older with type 2 diabetes, Boehringer Ingelheim and Eli Lilly and Company have announced. “As the burden of type 2 diabetes increases among young […]

June 22, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 21 Jun 2023

Nanobody company Attovia Therapeutics launches with $60M

Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of diseases, and Frazier Life Sciences, have launched Attovia Therapeutics, a company focused on creating a pipeline of biotherapeutics in immune-mediated disease and cancer. The company, based on Attobody, Alamar’s novel proprietary biparatopic nanobody platform, concurrently closed a $60 million Series A financing […]

June 21, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 21 Jun 2023

FDA clears T-Cell receptor natural killer cell therapy for sarcoma

Replay, a genome writing company, and The University of Texas MD Anderson Cancer Center (MD Anderson), have announced that the U.S. Food & Drug Administration (FDA) has issued a ‘safe to proceed’ for the Investigational New Drug (IND) application for NY-ESO-1 TCR/IL-15 NK, an engineered T-cell receptor natural killer (TCR-NK) cell therapy for advanced synovial […]

June 21, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 20 Jun 2023

BIO International Convention 2023: The Highlights

BIO International Convention, one of the largest networking events hosted for the biotech industry, has been influential in helping biopharmas discover new opportunities and building and strengthening partnerships within the biotech and pharma community. This year, the event took place from June 5 to 8, in the bustling biotech hotspot of Boston, Massachusetts, and saw […]

June 20, 2023 - 14 minutesmins - By Dylan Kissane

News and Trends 20 Jun 2023

NodThera announces positive inflammatory disease data

NodThera has announced positive data from first-in-human studies of its lead therapeutic candidates, NT-0249 and NT-0796. In the studies, both candidates were shown to clearly inhibit the NLRP3 inflammasome, a highly validated drug target that plays a pivotal role in controlling inflammatory diseases. The differentiated design characteristics of each candidate enabled them to penetrate different […]

June 20, 2023 - 3 minutesmins - By Jim Cornall

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

News and Trends

New disease characteristic seen as NMD Pharma reports Charcot-Marie-Tooth results

Breakthrough treatment for skin infections?

European Coalition for Access to Comprehensive Genomic Profiling launched

Sarepta gets approval for first gene therapy for Duchenne muscular dystrophy

SandboxAQ launches new division to boost drug development

Alchemab Therapeutics unveils Alzheimer’s candidate

Ovarian cancer study finds key genes for potential treatments

FDA approves type 2 diabetes drug for children 10 and older

Nanobody company Attovia Therapeutics launches with $60M

FDA clears T-Cell receptor natural killer cell therapy for sarcoma

BIO International Convention 2023: The Highlights

NodThera announces positive inflammatory disease data

Subscribe to our newsletter to get the latest biotech news!